Developer docs
API playgroundTry for free, no card

Search company profiles

Northwest Biotherapeutics

Full company profile

uuid0002euo

Namestring
Northwest Biotherapeutics
Legal namestring
Northwest Biotherapeutics, Inc.
Websiteurl
nwbio.com
Company typeenum
Public
Founded yearint
1998
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBethesda, United States
HQ citystring
Bethesda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
personalized cancer vaccines, dendritic cell immunotherapy, glioblastoma treatment, cell therapy manufacturing, oncology biologics
Industry3 codes
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy / Personalized Cell Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1DCVax-L Commercialization
TypeOne Time License
Description

The company is pursuing regulatory approval (MAA to UK MHRA) for commercial sale of DCVax-L for glioblastoma. As a personalized cell therapy, each treatment would be manufactured for individual patients using their own cells and tumor tissue.

nwbio.com
2DCVax-Direct and DCVax-Prostate Pipeline
TypeOne Time License
Description

Additional product candidates in clinical development for inoperable solid tumors and late-stage prostate cancer. Revenue would be generated upon successful regulatory approvals and commercialization.

nwbio.com
3Leukapheresis Services
TypeProfessional Services
Description

The company established its own dedicated leukapheresis clinic at The London Welbeck Hospital to provide leukapheresis services for other parties, potentially generating service revenue.

financialpost.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1DCVax
Description

Platform technology using activated dendritic cells to develop personalized cancer vaccines, including DCVax-L, DCVax-Direct, and DCVax-Prostate product lines

nwbio.com
Core offering1 text field

Northwest Biotherapeutics develops and is working to commercialize personalized dendritic cell-based cancer vaccines using its proprietary DCVax platform technology. The company's lead product candidate, DCVax-L, is in late-stage review for glioblastoma brain cancer with the UK MHRA, and additional pipeline candidates (DCVax-Direct, DCVax-Prostate) target inoperable solid tumors and late-stage prostate cancer respectively. The company also operates dedicated manufacturing infrastructure in the UK and a leukapheresis clinic to support scale-up of its immunotherapy programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 80% of patients achieved clinical benefits (longer delay in disease progression and longer extension of survival) in clinical trials to date
+2 more records
Product overview1 text field

Northwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines based on its DCVax® dendritic cell-based platform technology. The company has a portfolio of product candidates: DCVax-L (for glioblastoma brain cancer, Phase III completed), DCVax-Direct (for inoperable solid tumor cancers, Phase I/II), and DCVax-Prostate (for late-stage prostate cancer, Phase III cleared). All DCVax products are made from the patient's own dendritic cells, which are matured and activated using proprietary processes, then combined with tumor-specific antigens to mobilize the entire immune system against cancer. The company has also acquired Flaskworks automation technology for scalable manufacturing and Advent BioServices for integrated manufacturing operations.

Product and service1 record
1DCVax-L
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Advent BioServices Ltd.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-24
Description

Acquisition completed making Advent BioServices a wholly owned subsidiary. Advent is a UK-based contract development and manufacturing organization (CDMO) that had been partnering with the company. The acquisition aims to improve operational efficiency and scale up manufacturing capacity, streamline manufacturing, supply chain, and operational efficiencies.

prnewswire.co.uk
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-12
Description

Exclusive license for portfolio of dendritic cell technologies and intellectual property including 5 patent families filed in 2023. Technologies include enhanced dendritic cells, DC-based therapies, conditioning regimens, and approaches to reprogram tumor microenvironment. License terms include upfront fee, milestones up to $2.3 million, and 4% royalties on product sales.

3Cognate BioServices, Inc.
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2019-05-28
Description

Settlement agreement resolving past matters and providing for restart of DCVax-Direct production. Previously partnered on manufacturing of cell therapy products. New DCVax-Direct manufacturing agreement established.

nwbio.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2012-04-12
Description

Partnership to manufacture and deliver DCVax-L treatment for brain cancer patients as part of ongoing clinical trial for Glioblastoma multiforme in Europe. Includes both clinical trial and compassionate use programs.

5Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2011-05-18
Description

Partnership for production of DCVax-L for brain cancer for clinical trials and compassionate use cases in Europe. Fraunhofer is the largest applied research foundation in Europe with over 18,000 staff. Received $5.5 million German government grant for manufacturing and brain cancer trial at 30 sites in Germany.

nwbio.com
6Dr. Annalisa Jenkins
Strategic tierStrategicTypeOthers
Description

Strategic Adviser appointed to support development and expansion of DCVax dendritic cell-based cancer vaccine platform. Dr. Jenkins has over 25 years of biopharma leadership experience including CEO of Dimension Therapeutics and senior roles at Merck Serono and Bristol-Myers Squibb. Awarded Order of the British Empire (OBE).

nwbio.com
7Dr. Linda Liau
Strategic tierStrategicTypeOthers
Description

Joined the company's Scientific Advisory Board. Previously served as Principal Investigator of the Phase 3 trial of DCVax-L for treatment of glioblastoma. Currently Chair of the Department of Neurosurgery at UCLA.

nwbio.com
8Dr. Pawel Kalinski
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lead scientist-clinician from Roswell Park collaboration. Company plans to collaborate with Dr. Kalinski on further development of licensed dendritic cell technologies. Dr. Kalinski is one of the foremost experts on dendritic cell biology and therapies.

nwbio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cellectis develops allogeneic CAR-T cell therapies for oncology. Comparable as a cell therapy platform pursuing hematologic and solid tumor indications with novel gene editing approaches.

TypeDirect peer
Description

Dendreon's Provenge (sipuleucel-T) is the only commercially approved autologous dendritic cell therapy for cancer (prostate). Like NW Bio, Dendreon pioneered personalized DC-based cancer vaccines and serves as the most direct commercial precedent for DCVax-L.

TypeDirect peer
Description

Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, including Tecelra. Comparable in autologous cell therapy targeting solid tumors with personalized manufacturing.

TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Comparable as a cell therapy company pursuing multiple hematologic and solid tumor indications with platform-based development.

TypeBroad incumbent
Description

Moderna is developing mRNA-based personalized cancer vaccines (mRNA-4157) in combination with checkpoint inhibitors. Competes in the personalized cancer vaccine space with far greater resources and pipeline scale.

6BioNTech
TypeBroad incumbent
Description

BioNTech is a leading cancer immunotherapy company developing individualized mRNA cancer vaccines (BNT122) and other immune-targeted therapies. Overlaps with DCVax-L in the personalized cancer immunotherapy space, particularly for solid tumors.

TypeEmerging player
Description

Inovio develops DNA-based cancer vaccines and immunotherapies for HPV-related cancers and other solid tumors. Comparable as an emerging cancer vaccine platform targeting similar indications.

TypeBroad incumbent
Description

Bavarian Nordic develops therapeutic cancer vaccines (e.g., CV301, Prostvac) and is a broader oncology immunotherapy incumbent. Overlaps with DCVax in cancer vaccine positioning for solid tumors.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS owns cell therapy assets through Juno and Celgene (e.g., Breyanzi, Abecma) and the immuno-oncology franchise Opdivo. Broad incumbent competing in oncology cell therapy and immune checkpoint space relevant to DCVax combinations.

TypeDirect peer
Description

Iovance develops autologous cell therapies for solid tumors (TIL therapy, with FDA-approved Amtagvi for melanoma). Comparable in autologous cell therapy manufacturing complexity, regulatory pathway, and addressable solid tumor indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Northwest Biotherapeutics

Cancer Immunotherapy / Personalized Cell Therapynwbio.com

Northwest Biotherapeutics firmographics

Firmographics
Name
Northwest Biotherapeutics
Legal name
Northwest Biotherapeutics, Inc.
Website
https://nwbio.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Northwest Biotherapeutics industry classification

Industry
Product category
Cancer Immunotherapy / Personalized Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAJ
Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Personalized cancer vaccines
  • Dendritic cell immunotherapy
  • Glioblastoma treatment
  • Cell therapy manufacturing
  • Oncology biologics

Where Northwest Biotherapeutics is headquartered

Location

Headquarters

HQ city
Bethesda
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Northwest Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

  1. DCVax-L Commercialization: The company is pursuing regulatory approval (MAA to UK MHRA) for commercial sale of DCVax-L for glioblastoma. As a personalized cell therapy, each treatment would be manufactured for individual patients using their own cells and tumor tissue.
  2. DCVax-Direct and DCVax-Prostate Pipeline: Additional product candidates in clinical development for inoperable solid tumors and late-stage prostate cancer. Revenue would be generated upon successful regulatory approvals and commercialization.
  3. Leukapheresis Services: The company established its own dedicated leukapheresis clinic at The London Welbeck Hospital to provide leukapheresis services for other parties, potentially generating service revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Northwest Biotherapeutics product offering

Product offering

Core offering

Northwest Biotherapeutics develops and is working to commercialize personalized dendritic cell-based cancer vaccines using its proprietary DCVax platform technology. The company's lead product candidate, DCVax-L, is in late-stage review for glioblastoma brain cancer with the UK MHRA, and additional pipeline candidates (DCVax-Direct, DCVax-Prostate) target inoperable solid tumors and late-stage prostate cancer respectively. The company also operates dedicated manufacturing infrastructure in the UK and a leukapheresis clinic to support scale-up of its immunotherapy programs.

Product overview

Northwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines based on its DCVax® dendritic cell-based platform technology. The company has a portfolio of product candidates: DCVax-L (for glioblastoma brain cancer, Phase III completed), DCVax-Direct (for inoperable solid tumor cancers, Phase I/II), and DCVax-Prostate (for late-stage prostate cancer, Phase III cleared). All DCVax products are made from the patient's own dendritic cells, which are matured and activated using proprietary processes, then combined with tumor-specific antigens to mobilize the entire immune system against cancer. The company has also acquired Flaskworks automation technology for scalable manufacturing and Advent BioServices for integrated manufacturing operations.

Differentiator

Problem solved

Functional benefit

Brands

  • DCVax: Platform technology using activated dendritic cells to develop personalized cancer vaccines, including DCVax-L, DCVax-Direct, and DCVax-Prostate product lines

Products and services

  • DCVax-L

Quantifiable outcome

  • 80% of patients achieved clinical benefits (longer delay in disease progression and longer extension of survival) in clinical trials to date
  • +2 more outcomes

Companies that use Northwest Biotherapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Northwest Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Northwest Biotherapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and strategic.

  • Advent BioServices Ltd.coreTechnology or Integration · 24 October 2025Acquisition completed making Advent BioServices a wholly owned subsidiary. Advent is a UK-based contract development and manufacturing organization (CDMO) that had been partnering with the company. The acquisition aims to improve operational efficiency and scale up manufacturing capacity, streamline manufacturing, supply chain, and operational efficiencies.
  • Roswell Park Comprehensive Cancer CentercoreTechnology or Integration · 12 June 2024Exclusive license for portfolio of dendritic cell technologies and intellectual property including 5 patent families filed in 2023. Technologies include enhanced dendritic cells, DC-based therapies, conditioning regimens, and approaches to reprogram tumor microenvironment. License terms include upfront fee, milestones up to $2.3 million, and 4% royalties on product sales.
  • Cognate BioServices, Inc.strategicTechnology or Integration · 28 May 2019Settlement agreement resolving past matters and providing for restart of DCVax-Direct production. Previously partnered on manufacturing of cell therapy products. New DCVax-Direct manufacturing agreement established.
  • King's Health Partners (King's College Hospital and King's College London)strategicStrategic or Co-development Partner · 12 April 2012Partnership to manufacture and deliver DCVax-L treatment for brain cancer patients as part of ongoing clinical trial for Glioblastoma multiforme in Europe. Includes both clinical trial and compassionate use programs.
  • Fraunhofer Institute for Cell Therapy and Immunology (IZI)strategicTechnology or Integration · 18 May 2011Partnership for production of DCVax-L for brain cancer for clinical trials and compassionate use cases in Europe. Fraunhofer is the largest applied research foundation in Europe with over 18,000 staff. Received $5.5 million German government grant for manufacturing and brain cancer trial at 30 sites in Germany.
  • Dr. Annalisa JenkinsstrategicOthersStrategic Adviser appointed to support development and expansion of DCVax dendritic cell-based cancer vaccine platform. Dr. Jenkins has over 25 years of biopharma leadership experience including CEO of Dimension Therapeutics and senior roles at Merck Serono and Bristol-Myers Squibb. Awarded Order of the British Empire (OBE).
  • Dr. Linda LiaustrategicOthersJoined the company's Scientific Advisory Board. Previously served as Principal Investigator of the Phase 3 trial of DCVax-L for treatment of glioblastoma. Currently Chair of the Department of Neurosurgery at UCLA.
  • Dr. Pawel KalinskicoreStrategic or Co-development PartnerLead scientist-clinician from Roswell Park collaboration. Company plans to collaborate with Dr. Kalinski on further development of licensed dendritic cell technologies. Dr. Kalinski is one of the foremost experts on dendritic cell biology and therapies.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Northwest Biotherapeutics competitors and assessment

Company assessment

Emerging players

  • Cellectis: Cellectis develops allogeneic CAR-T cell therapies for oncology. Comparable as a cell therapy platform pursuing hematologic and solid tumor indications with novel gene editing approaches.
  • Inovio Pharmaceuticals: Inovio develops DNA-based cancer vaccines and immunotherapies for HPV-related cancers and other solid tumors. Comparable as an emerging cancer vaccine platform targeting similar indications.

Direct peers

  • Dendreon: Dendreon's Provenge (sipuleucel-T) is the only commercially approved autologous dendritic cell therapy for cancer (prostate). Like NW Bio, Dendreon pioneered personalized DC-based cancer vaccines and serves as the most direct commercial precedent for DCVax-L.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, including Tecelra. Comparable in autologous cell therapy targeting solid tumors with personalized manufacturing.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Comparable as a cell therapy company pursuing multiple hematologic and solid tumor indications with platform-based development.
  • Iovance Biotherapeutics: Iovance develops autologous cell therapies for solid tumors (TIL therapy, with FDA-approved Amtagvi for melanoma). Comparable in autologous cell therapy manufacturing complexity, regulatory pathway, and addressable solid tumor indications.

Broad incumbents

  • Moderna: Moderna is developing mRNA-based personalized cancer vaccines (mRNA-4157) in combination with checkpoint inhibitors. Competes in the personalized cancer vaccine space with far greater resources and pipeline scale.
  • BioNTech: BioNTech is a leading cancer immunotherapy company developing individualized mRNA cancer vaccines (BNT122) and other immune-targeted therapies. Overlaps with DCVax-L in the personalized cancer immunotherapy space, particularly for solid tumors.
  • Bavarian Nordic: Bavarian Nordic develops therapeutic cancer vaccines (e.g., CV301, Prostvac) and is a broader oncology immunotherapy incumbent. Overlaps with DCVax in cancer vaccine positioning for solid tumors.
  • Bristol-Myers Squibb: BMS owns cell therapy assets through Juno and Celgene (e.g., Breyanzi, Abecma) and the immuno-oncology franchise Opdivo. Broad incumbent competing in oncology cell therapy and immune checkpoint space relevant to DCVax combinations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Northwest Biotherapeutics social profiles

Digital presence

Northwest Biotherapeutics compliance and trust

Trust signal

Compliance2 records

Northwest Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Northwest Biotherapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Northwest Biotherapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Northwest Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Northwest Biotherapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Northwest Biotherapeutics

What does Northwest Biotherapeutics do?

Northwest Biotherapeutics develops and is working to commercialize personalized dendritic cell-based cancer vaccines using its proprietary DCVax platform technology. The company's lead product candidate, DCVax-L, is in late-stage review for glioblastoma brain cancer with the UK MHRA, and additional pipeline candidates (DCVax-Direct, DCVax-Prostate) target inoperable solid tumors and late-stage prostate cancer respectively. The company also operates dedicated manufacturing infrastructure in the UK and a leukapheresis clinic to support scale-up of its immunotherapy programs.

Is Northwest Biotherapeutics a public or private company?

Northwest Biotherapeutics is a public company. It is classified as public and is currently operating.

When was Northwest Biotherapeutics founded?

Northwest Biotherapeutics was founded in 1998. It employs 11 to 50 people.

Where is Northwest Biotherapeutics based?

Northwest Biotherapeutics is headquartered in Bethesda, United States, in the North America region.

How does Northwest Biotherapeutics make money?

Three revenue lines are on record. DCVax-L Commercialization is the primary driver. The others are DCVax-Direct and DCVax-Prostate Pipeline and leukapheresis Services.

Who are Northwest Biotherapeutics's main competitors?

Emerging players on record are Cellectis and Inovio Pharmaceuticals. Direct peers are Dendreon, Adaptimmune Therapeutics, Fate Therapeutics and Iovance Biotherapeutics. Broad incumbents are Moderna, BioNTech, Bavarian Nordic and Bristol-Myers Squibb.

Does Northwest Biotherapeutics have an API?

No public API is recorded for Northwest Biotherapeutics.

What industry is Northwest Biotherapeutics in?

Northwest Biotherapeutics's product category is Cancer Immunotherapy / Personalized Cell Therapy. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooNorthwest Biotherapeutics: Q3 Earnings SnapshotNorthwest Biotherapeutics reported a third-quarter loss of $28.8 million, or 2 cents per share. The cancer drug developer posted revenue of $883,000 for the period.PR NewswireNorthwest Biotherapeutics Announces Expansion of Its Technical TeamNorthwest Biotherapeutics expanded its US technical team, hiring a QA/Regulatory Affairs Manager, Director of Information Technologies, and Manager of Investor Relations. The company is also eliminating some positions to balance costs, with net headcount increase. It prioritizes scale-up of production capacity and preparations for clinical trials beyond brain cancer.TradingViewNorthwest Biotherapeutics Announces Expansion of Its Technical TeamNorthwest Biotherapeutics expanded its US technical team, hiring a QA/Regulatory Affairs Manager, Director of Information Technologies, and Manager of Investor Relations. The company also eliminated one position to balance costs, keeping operating expenses in the same range. It will continue reviewing personnel for its priority operations.Stock TitanNorthwest Biotherapeutics Expands US Technical TeamNorthwest Biotherapeutics expanded its US technical team, adding a QA/Regulatory Affairs Manager, IT Director, and Investor Relations Manager. The net headcount increase keeps operating costs in the same range as before, with one position terminated. The company is prioritizing production scale-up and clinical trial preparations.PR NewswireNorthwest Biotherapeutics Announces Expansion of Its Technical TeamNorthwest Biotherapeutics expanded its US technical team, hiring a QA/Regulatory Affairs Manager, Director of Information Technologies, and Manager of Investor Relations. The company also eliminated one position to balance costs, with further reviews planned. The expansion supports scale-up of production and preparations for clinical trials beyond brain cancer.Seeking AlphaNorthwest Biotherapeutics, NHSBT partners to expand DCVax-L production (NWBO:OTCMKTS)Northwest Biotherapeutics announced a collaboration with NHSBT to expand production of its experimental cancer vaccine DCVax-L for glioblastoma and other solid tumors. NHSBT will handle leukapheresis and cell processing, initially covering Leeds and Oxford with potential expansion across England.PR NewswireNorthwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionNorthwest Biotherapeutics and the UK National Health Service Blood and Transplant announced a collaboration to support production of DCVax-L, a personalized cancer vaccine for glioblastoma and solid tumors. NHSBT's therapeutic apheresis and cell processing teams will support manufacturing in Leeds and Oxford, with plans to expand to additional locations across England.YahooNorthwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionNorthwest Biotherapeutics and the UK National Health Service Blood and Transplant announced a collaboration to support production of DCVax-L, a personalized cancer vaccine. NHSBT's therapeutic apheresis and cell processing teams will support manufacturing, initially in Leeds and Oxford, with plans to expand to additional locations across England.Stock TitanNorthwest Biotherapeutics, NHSBT aid DCVax-L productionNorthwest Biotherapeutics and the UK's NHSBT announced a collaboration to support production of DCVax-L, a personalized cancer vaccine. NHSBT's therapeutic apheresis and cell processing teams will support manufacturing, initially in Leeds and Oxford, with plans to expand to additional locations across England.PR NewswireNorthwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L ProductionNorthwest Biotherapeutics and the UK National Health Service Blood and Transplant announced a collaboration to support production of DCVax-L, a personalized cancer vaccine for glioblastoma and solid tumors. NHSBT's therapeutic apheresis and cell processing teams will support manufacturing in Leeds and Oxford, with plans to expand to additional locations across England.